en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
1/2014
vol. 52
 
Share:
Share:
more
 
 
abstract:
Case report

Does early treatment of macrophage activation syndrome prevent fatal outcome in patients with severe systemic juvenile idiopathic arthritis?

Marzena Janczewska
,
Teresa Kołcun-Penkowska

Reumatologia 2014; 52, 1: 82–85
Online publish date: 2014/03/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Macrophage activation syndrome (MAS), a rare complication of various diseases, mainly systemic inflammatory connective tissue disorders, is being increasingly recognized. Most frequently MAS occurs in systemic juvenile idiopathic arthritis (sJIA), yet description of typical clinical features is challenging. Prognosis of the syndrome is often poor therefore prompt diagnosis and appropriate medical treatment are critical for survival.

We report the case of MAS diagnosed in a 7-year-old boy with severe generalized sJIA presenting description of our dilemmas associated with the diagnosis. We identified the condition as MAS on the basis of criteria defined by Ravelli et al. To make diagnosis of MAS was difficult, especially because some clinical symptoms are characteristic both for MAS and sJIA. Owing to deterioration of a general condition of the patient we took the risk of including treatment with cyclosporine. This treatment significantly improved the condition of the child and in our opinion prevented a fatal outcome.
keywords:

macrophage, activation, syndrome







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.